Citizens analyst Jason Butler lowered the firm’s price target on Avalo Therapeutics (AVTX) to $55 from $62 and keeps an Outperform rating on the shares. Positive Phase 2 LOTUS results support advancement to registrational studies, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty
- Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)
- Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler
- Avalo Therapeutics Announces Major Equity and Warrant Offering
- Avalo Therapeutics price target raised to $62 from $52 at Citizens